Legionellosis and biologic therapies

Bodro, M., Carratala, J. and Paterson, D. L. (2014) Legionellosis and biologic therapies. Respiratory Medicine, 108 8: 1223-1228. doi:10.1016/j.rmed.2014.04.017

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ339010_OA.pdf Full text (open access) application/pdf 343.92KB 4

Author Bodro, M.
Carratala, J.
Paterson, D. L.
Title Legionellosis and biologic therapies
Journal name Respiratory Medicine   Check publisher's open access policy
ISSN 0954-6111
Publication date 2014-08
Year available 2014
Sub-type Article (original research)
DOI 10.1016/j.rmed.2014.04.017
Open Access Status
Volume 108
Issue 8
Start page 1223
End page 1228
Total pages 6
Place of publication Camden, London, United Kingdom
Publisher Elsevier
Collection year 2015
Language eng
Abstract Background Biologic therapies are widely used in inflammatory diseases, and they are associated to an increased infection risk, especially to granulomatous and intracellular infections such as Legionella. Results A review of the literature revealed 105 cases of Legionella pneumonia in patients taking biologic therapies. Sixty-four patients (65.3%) were treated with infliximab, 23 (23.5%) with adalimumab, 5 (5%) with etanercept and 3 (3%) with rituximab. Seventy-one per cent of the patients were treated for rheumatologic diseases and 16% for inflammatory bowel diseases. The majority of the patients received one or more concomitant immunosuppressive drugs, especially steroids (43%). Overall mortality was 19%. Legionella pneumonia might complicate therapy with biologic therapies, especially in patients being treated with infliximab or adalimumab given concomitantly with other immunosuppressive medications during their first 6 months of treatment. Conclusion Physicians should be aware of this potentially severe association. Early recognition and treatment would likely result in reduced morbidity and mortality.
Keyword Biologic therapies
Immunocompromised patients
Tumour necrosis factor alpha inhibitors
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: UQ Centre for Clinical Research Publications
Official 2015 Collection
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 2 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 09 Sep 2014, 02:39:39 EST by System User on behalf of UQ Centre for Clinical Research